Brief: Novan Reports Positive Topline Results From Pivotal Phase 3 Trial Of SB206 In Patients With Molluscum Contagiosum

NVN Liquidation

11/06/2021 11:38

June 11 (Reuters) - Novan Inc  NOVN.O :
    * NOVAN REPORTS POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE
3
TRIAL OF SB206 IN PATIENTS WITH MOLLUSCUM CONTAGIOSUM
    * NOVAN INC - NOVAN INTENDS TO SUBMIT NEW DRUG APPLICATION
("NDA")
NO LATER THAN Q3 OF 2022
    * NOVAN INC - B-SIMPLE4 ACHIEVES STATISTICAL SIGNIFICANCE
FOR
PRIMARY ENDPOINT WITH P-VALUE LESS THAN 0.0001
    * NOVAN INC - NO SERIOUS ADVERSE EVENTS RELATED TO TREATMENT
WITH
SB206

Source text for Eikon:  ID:nGNX11MRYg 
Further company coverage:  NOVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))